Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population in Canada, the United States, and Europe. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert for detecting smoking status; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer’s disease. The company was founded in 1989 and is headquartered in Nassau, Bahamas.
Metrics to compare | NYMXF | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNYMXFPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.1x | −2.3x | −0.5x | |
PEG Ratio | 0.01 | −0.06 | 0.00 | |
Price / Book | −1.5x | 1.4x | 2.6x | |
Price / LTM Sales | - | 6.9x | 3.0x | |
Upside (Analyst Target) | - | 239.3% | 56.3% | |
Fair Value Upside | Unlock | 25.4% | 10.0% | Unlock |